董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Erick Lucera | 男 | Director | 58 | 1.70万美元 | 1.20 | 2026-06-26 |
| William Forbes | 男 | Director | 64 | 1.70万美元 | 1.00 | 2026-06-26 |
| Yoori Lee | 女 | Director | 53 | 1.70万美元 | 1.02 | 2026-06-26 |
| Robert S. Goodman | 男 | Chief Executive Officer and Director | 61 | 13.30万美元 | 未持股 | 2026-06-26 |
| Robert F. Carey | 男 | Chairman and Director | 67 | 1.70万美元 | 145.10 | 2026-06-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel Moorhead | 男 | Chief Financial Officer | 53 | 12.06万美元 | 未持股 | 2026-06-26 |
| Michael Gaul | 男 | Chief Operating Officer | 72 | 39.69万美元 | 1.02 | 2026-06-26 |
| Robert S. Goodman | 男 | Chief Executive Officer and Director | 61 | 13.30万美元 | 未持股 | 2026-06-26 |
董事简历
中英对照 | 中文 | 英文- Erick Lucera
-
Erick J. Lucera于2017年8月加入Beyond Air, Inc.董事会。他被任命为AVEO Oncology（Nasdaq：AVEO）的首席财务官，AVEO Oncology是一家在纳斯达克上市的生物制药公司，2020年专注于满足肿瘤和其他未满足的医疗需求的靶向药物。2016年至2019年，Lucera先生担任Valeritas Holdings, Inc.（一家在美国纳斯达克上市的商业公司，开发糖尿病新技术）的首席财务官。Lucera先生于2015年至2016年担任Viventia Bio首席财务官、财务主管兼秘书。2012年至2015年，他在兽用生物制药公司Aratana Therapeutics担任企业发展副总裁。在Aratana任职期间，他通过一系列收购和通过五次公开和非公开发行融资近2.5亿美元的授权交易，帮助扩大了公司的产品线。在担任医疗保健公司高管之前，Lucera先生在投资管理领域度过了超过15年，曾担任Eaton Vance公司的医疗保健分析师、Intrepid Capital的铁人三项生命科学基金的投资组合经理以及Independence Investments的医疗保健研究团队负责人。自2021年10月起，他担任Bone Biologics的董事会成员，Bone Biologics是一家在纳斯达克上市的生物制剂公司。他拥有哈佛大学公共卫生证书、波士顿学院量化金融硕士学位、印第安纳大学布卢明顿分校MBA学位和特拉华大学会计学学士学位。Lucera先生已获得CFA、CMA和注册会计师称号。
Erick Lucera,has served as a member of the Board since April 2023. Since March 2025, Mr. Lucera has served as Chief Financial Officer of Dyne Therapeutics, a publicly traded biotechnology company focusing on functional improvement for people living with genetically driven neuromuscular diseases. From May 2023 to March 2025 Mr. Lucera served as Executive Vice President and Chief Financial Officer of Editas Medicine, a publicly traded clinical stage biotechnology company. From 2020 to February 2023, Mr. Lucera served as Chief Financial Officer of AVEO Oncology, a public biotech company, and subsequent to the close of its acquisition, worked on integration with LG Chem, Ltd. From 2016 to 2020, Mr. Lucera served as Chief Financial Officer, Treasurer and Secretary of VALERITAS, a publicly traded commercial-stage medical technology company where he led multiple successful public offerings. From 2017 to the present, Mr. Lucera has served as a member of the Board of Directors and Audit Committee Chairman of Beyond Air, a publicly held commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide generators and delivery systems. From 2021 to the present, Mr. Lucera has served as a member of the Board of Directors and Audit Committee Chairman of Bone Biologics Corporation, a publicly held company focusing on regenerative medicine therapies to treat bone disorders. From 2015 to 2016, Mr. Lucera served as Chief Financial Officer, Treasurer and Secretary of VIVENTIA Bio, acquired by Eleven Biotherapeutics, Inc., now Sesen Bio, a biotechnology company focused on developing targeted protein therapeutics for the treatment of cancer. Early in his career, Mr. Lucera spent more than 15 years covering healthcare and the life sciences in investment management. - Erick J. Lucera于2017年8月加入Beyond Air, Inc.董事会。他被任命为AVEO Oncology（Nasdaq：AVEO）的首席财务官，AVEO Oncology是一家在纳斯达克上市的生物制药公司，2020年专注于满足肿瘤和其他未满足的医疗需求的靶向药物。2016年至2019年，Lucera先生担任Valeritas Holdings, Inc.（一家在美国纳斯达克上市的商业公司，开发糖尿病新技术）的首席财务官。Lucera先生于2015年至2016年担任Viventia Bio首席财务官、财务主管兼秘书。2012年至2015年，他在兽用生物制药公司Aratana Therapeutics担任企业发展副总裁。在Aratana任职期间，他通过一系列收购和通过五次公开和非公开发行融资近2.5亿美元的授权交易，帮助扩大了公司的产品线。在担任医疗保健公司高管之前，Lucera先生在投资管理领域度过了超过15年，曾担任Eaton Vance公司的医疗保健分析师、Intrepid Capital的铁人三项生命科学基金的投资组合经理以及Independence Investments的医疗保健研究团队负责人。自2021年10月起，他担任Bone Biologics的董事会成员，Bone Biologics是一家在纳斯达克上市的生物制剂公司。他拥有哈佛大学公共卫生证书、波士顿学院量化金融硕士学位、印第安纳大学布卢明顿分校MBA学位和特拉华大学会计学学士学位。Lucera先生已获得CFA、CMA和注册会计师称号。
- Erick Lucera,has served as a member of the Board since April 2023. Since March 2025, Mr. Lucera has served as Chief Financial Officer of Dyne Therapeutics, a publicly traded biotechnology company focusing on functional improvement for people living with genetically driven neuromuscular diseases. From May 2023 to March 2025 Mr. Lucera served as Executive Vice President and Chief Financial Officer of Editas Medicine, a publicly traded clinical stage biotechnology company. From 2020 to February 2023, Mr. Lucera served as Chief Financial Officer of AVEO Oncology, a public biotech company, and subsequent to the close of its acquisition, worked on integration with LG Chem, Ltd. From 2016 to 2020, Mr. Lucera served as Chief Financial Officer, Treasurer and Secretary of VALERITAS, a publicly traded commercial-stage medical technology company where he led multiple successful public offerings. From 2017 to the present, Mr. Lucera has served as a member of the Board of Directors and Audit Committee Chairman of Beyond Air, a publicly held commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide generators and delivery systems. From 2021 to the present, Mr. Lucera has served as a member of the Board of Directors and Audit Committee Chairman of Bone Biologics Corporation, a publicly held company focusing on regenerative medicine therapies to treat bone disorders. From 2015 to 2016, Mr. Lucera served as Chief Financial Officer, Treasurer and Secretary of VIVENTIA Bio, acquired by Eleven Biotherapeutics, Inc., now Sesen Bio, a biotechnology company focused on developing targeted protein therapeutics for the treatment of cancer. Early in his career, Mr. Lucera spent more than 15 years covering healthcare and the life sciences in investment management.
- William Forbes
-
William Forbes于2018年8月加入我们的董事会。福布斯博士目前担任Vivelix Pharmaceuticals，Ltd.的创始人，总裁兼首席执行官，该公司是一家临床阶段的制药公司，自2016年以来专注于胃肠道疾病。创立Vivelix公司之前，Forbes博士曾任职Salix Pharmaceuticals公司，担任首席开发官，也曾担任医疗和研发主管。在加入Salix之前，Forbes博士在多家全球制药公司从事了15年的临床开发&法规事务和临床研究。
William Forbes joined Beyond Air, Inc.'s Board of Directors in August 2018 and serves on Beyond Air, Inc.'s compensation and nominating committee. He has to Beyond Air, Inc.'s Board of Directors more than 30 years of pharmaceutical product development experience and, working with health authorities in the U.S. and Europe, has contributed to numerous marketing approvals spanning a diverse range of therapeutic areas. Dr. Forbes has served as the Chief Development Officer of Trevi Therapeutics, a clinical stage pharmaceutical company focused on serious neurologically mediated diseases since February 2021. Prior to joining Trevi, Dr. Forbes was at Salix Pharmaceuticals as the Chief Development Officer and also Head of Medical and R&D from February 2015 to June 2015. Prior to Salix, Dr. Forbes spent 15 years in Clinical Development & Regulatory Affairs and Clinical Research at a number of global pharmaceutical companies. - William Forbes于2018年8月加入我们的董事会。福布斯博士目前担任Vivelix Pharmaceuticals，Ltd.的创始人，总裁兼首席执行官，该公司是一家临床阶段的制药公司，自2016年以来专注于胃肠道疾病。创立Vivelix公司之前，Forbes博士曾任职Salix Pharmaceuticals公司，担任首席开发官，也曾担任医疗和研发主管。在加入Salix之前，Forbes博士在多家全球制药公司从事了15年的临床开发&法规事务和临床研究。
- William Forbes joined Beyond Air, Inc.'s Board of Directors in August 2018 and serves on Beyond Air, Inc.'s compensation and nominating committee. He has to Beyond Air, Inc.'s Board of Directors more than 30 years of pharmaceutical product development experience and, working with health authorities in the U.S. and Europe, has contributed to numerous marketing approvals spanning a diverse range of therapeutic areas. Dr. Forbes has served as the Chief Development Officer of Trevi Therapeutics, a clinical stage pharmaceutical company focused on serious neurologically mediated diseases since February 2021. Prior to joining Trevi, Dr. Forbes was at Salix Pharmaceuticals as the Chief Development Officer and also Head of Medical and R&D from February 2015 to June 2015. Prior to Salix, Dr. Forbes spent 15 years in Clinical Development & Regulatory Affairs and Clinical Research at a number of global pharmaceutical companies.
- Yoori Lee
-
Yoori Lee于2018年1月加入我们的董事会。她自2013年起担任Trio Health Advisory Group，Inc.联合创始人和总裁。Trio Health的使命是通过协调所有患者护理利益相关者的努力来提高患者护理结果的护理质量。在加入Trio Health之前，Lee女士在Leerink Partners LLC（一家领先的梦百合投资银行）任职超过15年，在那里她担任董事总经理和MedaCorp Services的董事。此外，她还帮助建立了MedaCorp网络，这是一支专家队伍，包括临床医学、生物医学研究、监管事务、公共政策、梦百合管理和梦百合信息技术等不同领域的35000多名梦百合专业人员。
Yoori Lee joined Beyond Air, Inc.'s Board of Directors in January 2018. Ms. Lee serves on Beyond Air, Inc.'s compensation committee and audit committee. She has served as Co founder and President of Trio Health Advisory Group, Inc. since 2013. Trio Health's mission is to improve the quality of care in patient outcomes through coordinating the efforts of all patient care stakeholders. Prior to Trio Health, Ms. Lee spent over 15 years at Leerink Partners LLC, a leading healthcare investment bank, where she was Managing Director, and Director of MEDACorp Services. Additionally, she helped found the MEDACorp network, a cadre of experts including more than 35,000 healthcare professionals in diverse areas of practice such as clinical medicine, biomedical research, regulatory affairs, public policy, healthcare administration and healthcare information technology. - Yoori Lee于2018年1月加入我们的董事会。她自2013年起担任Trio Health Advisory Group，Inc.联合创始人和总裁。Trio Health的使命是通过协调所有患者护理利益相关者的努力来提高患者护理结果的护理质量。在加入Trio Health之前，Lee女士在Leerink Partners LLC（一家领先的梦百合投资银行）任职超过15年，在那里她担任董事总经理和MedaCorp Services的董事。此外，她还帮助建立了MedaCorp网络，这是一支专家队伍，包括临床医学、生物医学研究、监管事务、公共政策、梦百合管理和梦百合信息技术等不同领域的35000多名梦百合专业人员。
- Yoori Lee joined Beyond Air, Inc.'s Board of Directors in January 2018. Ms. Lee serves on Beyond Air, Inc.'s compensation committee and audit committee. She has served as Co founder and President of Trio Health Advisory Group, Inc. since 2013. Trio Health's mission is to improve the quality of care in patient outcomes through coordinating the efforts of all patient care stakeholders. Prior to Trio Health, Ms. Lee spent over 15 years at Leerink Partners LLC, a leading healthcare investment bank, where she was Managing Director, and Director of MEDACorp Services. Additionally, she helped found the MEDACorp network, a cadre of experts including more than 35,000 healthcare professionals in diverse areas of practice such as clinical medicine, biomedical research, regulatory affairs, public policy, healthcare administration and healthcare information technology.
- Robert S. Goodman
-
Robert S. Goodman，于2025年6月加入董事会。古德曼先生为《财富》50强企业带来了30多年的执行商业领导经验和跨越风险投资支持的新兴业务的成功。最近，他在开创性的健康科技公司Fourth Frontier的董事会任职，在那里他为该公司的510k FDA设备批准做出了贡献，并支持了成功的B轮融资。Goodman先生在2023-2024年期间担任制药公司WEP Clinical的首席商务官，帮助加速并提高了总合同价值和收入同比增长超过30%。古德曼先生曾在BioTelemetry担任部门总裁，并在2021年带领皇家飞利浦进行了一笔2.1亿美元的卖方交易。Goodman先生还拥有丰富的执行销售经验，曾于2008-2017年担任Cardiocore（后被BioTelemetry收购）的销售与营销高级副总裁，并于2007-2008年担任赛默飞世尔的高级董事、销售与营销主管。
Robert S. Goodman was appointed as a director of the Company on June 16, 2025. Mr. Goodman has also served as Chief Commercial Officer since November 2025. He was appointed to serve as the Chief Executive Officer. He has over 25 years of experience in sales strategy, go to market execution, strategic partnerships and growth management. He has been instrumental in shaping the Company's recent commercial approach and is widely recognized for his ability to expand market penetration and accelerate product adoption in competitive healthcare sectors. Prior to joining Beyond Air, Mr. Goodman served as Chief Commercial Officer at WEP Clinical from 2023 to 2024, and ActiGraph from 2022 to 2023, where he led global commercial operations and go to market execution. Earlier in his career, he spent more than nine years at BioTelemetry, Inc. (acquired by Royal Philips), including as Division President and Business Head of BioTel Care and Alliance from and Senior Vice President of Global Sales and Marketing at BioTel Research, helping scale multiple businesses through periods of accelerated growth and strategic transformation. He previously held senior leadership roles at Cardiocore (acquired by BioTelemetry), Thermo Fisher Scientific, and Pfizer, where he spent 15 years in progressively senior commercial positions. Mr. Goodman currently serves on the board of Fourth Frontier. He is a retired U.S. Army officer and holds a B.S. degree from Norwich University. - Robert S. Goodman，于2025年6月加入董事会。古德曼先生为《财富》50强企业带来了30多年的执行商业领导经验和跨越风险投资支持的新兴业务的成功。最近，他在开创性的健康科技公司Fourth Frontier的董事会任职，在那里他为该公司的510k FDA设备批准做出了贡献，并支持了成功的B轮融资。Goodman先生在2023-2024年期间担任制药公司WEP Clinical的首席商务官，帮助加速并提高了总合同价值和收入同比增长超过30%。古德曼先生曾在BioTelemetry担任部门总裁，并在2021年带领皇家飞利浦进行了一笔2.1亿美元的卖方交易。Goodman先生还拥有丰富的执行销售经验，曾于2008-2017年担任Cardiocore（后被BioTelemetry收购）的销售与营销高级副总裁，并于2007-2008年担任赛默飞世尔的高级董事、销售与营销主管。
- Robert S. Goodman was appointed as a director of the Company on June 16, 2025. Mr. Goodman has also served as Chief Commercial Officer since November 2025. He was appointed to serve as the Chief Executive Officer. He has over 25 years of experience in sales strategy, go to market execution, strategic partnerships and growth management. He has been instrumental in shaping the Company's recent commercial approach and is widely recognized for his ability to expand market penetration and accelerate product adoption in competitive healthcare sectors. Prior to joining Beyond Air, Mr. Goodman served as Chief Commercial Officer at WEP Clinical from 2023 to 2024, and ActiGraph from 2022 to 2023, where he led global commercial operations and go to market execution. Earlier in his career, he spent more than nine years at BioTelemetry, Inc. (acquired by Royal Philips), including as Division President and Business Head of BioTel Care and Alliance from and Senior Vice President of Global Sales and Marketing at BioTel Research, helping scale multiple businesses through periods of accelerated growth and strategic transformation. He previously held senior leadership roles at Cardiocore (acquired by BioTelemetry), Thermo Fisher Scientific, and Pfizer, where he spent 15 years in progressively senior commercial positions. Mr. Goodman currently serves on the board of Fourth Frontier. He is a retired U.S. Army officer and holds a B.S. degree from Norwich University.
- Robert F. Carey
-
Robert F. Carey于2019年2月加入Beyond Air，Inc.董事会。他帮助生物技术和专业制药公司通过首次公开发行、后续发行、债务发行和私募融资筹集了超过100亿美元。他曾担任并购和战略联盟交易的财务顾问，总交易价值超过100亿美元。Carey先生共同创立了ACELYRIN，Inc.，并担任该公司的总裁兼首席运营官，该公司是一家生物制药公司，将投资、开发和商业化改变生命的药物疗法。Carey先生曾于2014年3月至2019年9月担任Horizon Therapeutics plc的执行副总裁兼首席业务官，在此期间，Horizon therrapeutics斥资超过35亿美元收购或许可了8种商业产品和3种正在开发的产品，净销售额从2013年的7400万美元增长至2018年的约12亿美元，复合年增长率为75%。在Horizon之前，他曾在JMP证券担任常务董事兼生命科学投资银行集团负责人超过11年。Carey先生还是Dresdner Kleinwort Wasserstein和Vector Securities医疗集团的董事总经理。他在圣母大学获得会计学学士学位。Carey先生目前担任Sangamo Therapeutics，Inc.股份有限公司和Hawthorne Race Course，Inc.股份有限公司的董事会成员，并曾于2020年7月至2021年2月担任双子治疗学股份有限公司的Disk Medicine，Inc.董事会成员。
Robert F. Carey joined Beyond Air, Inc.'s Board of Directors in February 2019 and serves as Chairman and as a Member on Beyond Air, Inc.'s audit and nominating committee. He has an extensive track record of accomplishment within the biopharmaceutical and healthcare investment banking industry. He has assisted biotech and specialty pharma companies raise more than $10 billion in initial public offerings, follow on offerings, debt offerings, and private placements. He has served as a financial advisor on mergers, acquisitions, and strategic alliance transactions with a total deal value of more than $10 billion. From July 2020 until December 2023, Mr. Carey was co founder and President of ACELYRIN, INC., a biopharmaceutical company developing life changing drug therapies. Mr. Carey previously served as Executive Vice President and Chief Business Officer at Horizon Therapeutics plc from March 2014 to September 2019, during which Horizon Therapeutics deployed in excess of $3.5 billion to acquire or license eight commercial products and three products in development and grew net sales from $74 million in 2013 to approximately $1.2 billion in 2018, a compound annual growth rate of 75%. Before Horizon, he spent more than 11 years as Managing Director and Head of the Life Sciences Investment Banking Group at JMP Securities. Mr. Carey was also Managing Director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities. He received his B.B.A. in Accounting from the University of Notre Dame. Mr. Carey currently serves on the Board of Beyond Cancer Ltd. and Sangamo Therapeutics, Inc. - Robert F. Carey于2019年2月加入Beyond Air，Inc.董事会。他帮助生物技术和专业制药公司通过首次公开发行、后续发行、债务发行和私募融资筹集了超过100亿美元。他曾担任并购和战略联盟交易的财务顾问，总交易价值超过100亿美元。Carey先生共同创立了ACELYRIN，Inc.，并担任该公司的总裁兼首席运营官，该公司是一家生物制药公司，将投资、开发和商业化改变生命的药物疗法。Carey先生曾于2014年3月至2019年9月担任Horizon Therapeutics plc的执行副总裁兼首席业务官，在此期间，Horizon therrapeutics斥资超过35亿美元收购或许可了8种商业产品和3种正在开发的产品，净销售额从2013年的7400万美元增长至2018年的约12亿美元，复合年增长率为75%。在Horizon之前，他曾在JMP证券担任常务董事兼生命科学投资银行集团负责人超过11年。Carey先生还是Dresdner Kleinwort Wasserstein和Vector Securities医疗集团的董事总经理。他在圣母大学获得会计学学士学位。Carey先生目前担任Sangamo Therapeutics，Inc.股份有限公司和Hawthorne Race Course，Inc.股份有限公司的董事会成员，并曾于2020年7月至2021年2月担任双子治疗学股份有限公司的Disk Medicine，Inc.董事会成员。
- Robert F. Carey joined Beyond Air, Inc.'s Board of Directors in February 2019 and serves as Chairman and as a Member on Beyond Air, Inc.'s audit and nominating committee. He has an extensive track record of accomplishment within the biopharmaceutical and healthcare investment banking industry. He has assisted biotech and specialty pharma companies raise more than $10 billion in initial public offerings, follow on offerings, debt offerings, and private placements. He has served as a financial advisor on mergers, acquisitions, and strategic alliance transactions with a total deal value of more than $10 billion. From July 2020 until December 2023, Mr. Carey was co founder and President of ACELYRIN, INC., a biopharmaceutical company developing life changing drug therapies. Mr. Carey previously served as Executive Vice President and Chief Business Officer at Horizon Therapeutics plc from March 2014 to September 2019, during which Horizon Therapeutics deployed in excess of $3.5 billion to acquire or license eight commercial products and three products in development and grew net sales from $74 million in 2013 to approximately $1.2 billion in 2018, a compound annual growth rate of 75%. Before Horizon, he spent more than 11 years as Managing Director and Head of the Life Sciences Investment Banking Group at JMP Securities. Mr. Carey was also Managing Director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities. He received his B.B.A. in Accounting from the University of Notre Dame. Mr. Carey currently serves on the Board of Beyond Cancer Ltd. and Sangamo Therapeutics, Inc.
高管简历
中英对照 | 中文 | 英文- Daniel Moorhead
Daniel Moorhead，2017年6月加入，担任首席财务官，负责所有财务和会计职能。在加入Zynex之前，Moorhead先生是EvolvingSystems，Inc.的首席财务官2016年1月至2017年5月，曾担任财务和行政Vice President（2011年12月至2015年12月）和其他财务管理职务（2002年至2005年和2008年至2011年）。Moorhead先生是一名注册会计师，并持有the University of Northern Colorado会计学的B.B.A.。
Daniel Moorhead was appointed to serve as the Chief Financial Officer of the Company effective as of January 5, 2026. Mr. Moorhead most recently served as the Chief Financial Officer of Zynex, Inc. from June 2017 to August 2025. Prior to his role with Zynex, Mr. Moorhead previously served as Chief Financial Officer of Evolving Systems, Inc. (Nasdaq: EVOL) from January 2016 until May 2017, after having served as Vice President of Finance & Administration from December 2011 through December 2015 and in other financial management roles from 2002 2005 and 2008 2011. Mr. Moorhead is a CPA and holds a B.B.A. in Accounting from the University of Northern Colorado.- Daniel Moorhead，2017年6月加入，担任首席财务官，负责所有财务和会计职能。在加入Zynex之前，Moorhead先生是EvolvingSystems，Inc.的首席财务官2016年1月至2017年5月，曾担任财务和行政Vice President（2011年12月至2015年12月）和其他财务管理职务（2002年至2005年和2008年至2011年）。Moorhead先生是一名注册会计师，并持有the University of Northern Colorado会计学的B.B.A.。
- Daniel Moorhead was appointed to serve as the Chief Financial Officer of the Company effective as of January 5, 2026. Mr. Moorhead most recently served as the Chief Financial Officer of Zynex, Inc. from June 2017 to August 2025. Prior to his role with Zynex, Mr. Moorhead previously served as Chief Financial Officer of Evolving Systems, Inc. (Nasdaq: EVOL) from January 2016 until May 2017, after having served as Vice President of Finance & Administration from December 2011 through December 2015 and in other financial management roles from 2002 2005 and 2008 2011. Mr. Moorhead is a CPA and holds a B.B.A. in Accounting from the University of Northern Colorado.
- Michael Gaul
Michael Gaul自2022年7月1日起担任Beyond Air, Inc.首席运营官。高卢先生于2020年5月加入公司，担任运营高级副总裁，这一头衔一直保持到2022年6月。高卢先生曾在运营、销售和营销、供应链、分销、质量、监管、人力资源和财务等领域领导团队。他曾在美国和亚洲的多家工厂担任过P & L方面的经验，包括2011年9月至2020年2月在海事防务承包商Sparton Corporation（制造与设计服务业务部门集团副总裁；医疗业务部门集团副总裁）任职，2005年6月至2011年2月在商业认可的全人工心脏制造商和供应商SynCardia Systems（COO；运营副总裁）任职，2003年9月至2005年2月在医疗器械公司Ventana Medical Systems（现名Roche Tissue Diagnostics）（副总裁兼运营总经理）任职，以及Robotic Vision Systems，Inc.（总经理，先锋部；系统部运营副总裁），机器视觉系统制造商，1997年9月至2003年6月。他目前还担任俄亥俄州生命科学协会的董事会成员，以支持和促进俄亥俄州的生物科学产业。高卢先生拥有特拉华谷大学工商管理学士学位和佛罗里达理工学院工商管理硕士学位。
Michael Gaul has been Beyond Air, Inc.'s Chief Operating Officer since July 1, 2022. Mr. Gaul joined the Company in May 2020 as Senior VP, Operations, a title he held until June 2022. Mr. Gaul has led teams in operations, sales and marketing, supply chain, distribution, quality, regulatory, human resources, and finance. He has had P&L experience with multi plant responsibility in both the U.S. and Asia, including roles with Sparton Corporation (Group VP, Manufacturing & Design Services Business Unit; Group VP, Medical Business Unit), a defense contractor for maritime defense, from September 2011 to February 2020, SynCardia Systems (COO; VP Operations), a manufacturer and provider of the commercially approved Total Artificial Heart, from June 2005 to February 2011, Ventana Medical Systems (now known as Roche Tissue Diagnostics) (VP & General Manager, Operations), a medical device company, from September 2003 to April 2005, and Robotic Vision Systems, Inc. (General Manager, Vanguard Division; VP Operations, Systemation Division), a maker of machine vision systems, from September 1997 to June 2003. He also currently serves on the Board of Directors of the Ohio Life Sciences Association to support and promote Ohio's bioscience industry. Mr. Gaul has a BS, Business Administration from Delaware Valley University, and an MBA from Florida Institute of Technology.- Michael Gaul自2022年7月1日起担任Beyond Air, Inc.首席运营官。高卢先生于2020年5月加入公司，担任运营高级副总裁，这一头衔一直保持到2022年6月。高卢先生曾在运营、销售和营销、供应链、分销、质量、监管、人力资源和财务等领域领导团队。他曾在美国和亚洲的多家工厂担任过P & L方面的经验，包括2011年9月至2020年2月在海事防务承包商Sparton Corporation（制造与设计服务业务部门集团副总裁；医疗业务部门集团副总裁）任职，2005年6月至2011年2月在商业认可的全人工心脏制造商和供应商SynCardia Systems（COO；运营副总裁）任职，2003年9月至2005年2月在医疗器械公司Ventana Medical Systems（现名Roche Tissue Diagnostics）（副总裁兼运营总经理）任职，以及Robotic Vision Systems，Inc.（总经理，先锋部；系统部运营副总裁），机器视觉系统制造商，1997年9月至2003年6月。他目前还担任俄亥俄州生命科学协会的董事会成员，以支持和促进俄亥俄州的生物科学产业。高卢先生拥有特拉华谷大学工商管理学士学位和佛罗里达理工学院工商管理硕士学位。
- Michael Gaul has been Beyond Air, Inc.'s Chief Operating Officer since July 1, 2022. Mr. Gaul joined the Company in May 2020 as Senior VP, Operations, a title he held until June 2022. Mr. Gaul has led teams in operations, sales and marketing, supply chain, distribution, quality, regulatory, human resources, and finance. He has had P&L experience with multi plant responsibility in both the U.S. and Asia, including roles with Sparton Corporation (Group VP, Manufacturing & Design Services Business Unit; Group VP, Medical Business Unit), a defense contractor for maritime defense, from September 2011 to February 2020, SynCardia Systems (COO; VP Operations), a manufacturer and provider of the commercially approved Total Artificial Heart, from June 2005 to February 2011, Ventana Medical Systems (now known as Roche Tissue Diagnostics) (VP & General Manager, Operations), a medical device company, from September 2003 to April 2005, and Robotic Vision Systems, Inc. (General Manager, Vanguard Division; VP Operations, Systemation Division), a maker of machine vision systems, from September 1997 to June 2003. He also currently serves on the Board of Directors of the Ohio Life Sciences Association to support and promote Ohio's bioscience industry. Mr. Gaul has a BS, Business Administration from Delaware Valley University, and an MBA from Florida Institute of Technology.
- Robert S. Goodman
Robert S. Goodman，于2025年6月加入董事会。古德曼先生为《财富》50强企业带来了30多年的执行商业领导经验和跨越风险投资支持的新兴业务的成功。最近，他在开创性的健康科技公司Fourth Frontier的董事会任职，在那里他为该公司的510k FDA设备批准做出了贡献，并支持了成功的B轮融资。Goodman先生在2023-2024年期间担任制药公司WEP Clinical的首席商务官，帮助加速并提高了总合同价值和收入同比增长超过30%。古德曼先生曾在BioTelemetry担任部门总裁，并在2021年带领皇家飞利浦进行了一笔2.1亿美元的卖方交易。Goodman先生还拥有丰富的执行销售经验，曾于2008-2017年担任Cardiocore（后被BioTelemetry收购）的销售与营销高级副总裁，并于2007-2008年担任赛默飞世尔的高级董事、销售与营销主管。
Robert S. Goodman was appointed as a director of the Company on June 16, 2025. Mr. Goodman has also served as Chief Commercial Officer since November 2025. He was appointed to serve as the Chief Executive Officer. He has over 25 years of experience in sales strategy, go to market execution, strategic partnerships and growth management. He has been instrumental in shaping the Company's recent commercial approach and is widely recognized for his ability to expand market penetration and accelerate product adoption in competitive healthcare sectors. Prior to joining Beyond Air, Mr. Goodman served as Chief Commercial Officer at WEP Clinical from 2023 to 2024, and ActiGraph from 2022 to 2023, where he led global commercial operations and go to market execution. Earlier in his career, he spent more than nine years at BioTelemetry, Inc. (acquired by Royal Philips), including as Division President and Business Head of BioTel Care and Alliance from and Senior Vice President of Global Sales and Marketing at BioTel Research, helping scale multiple businesses through periods of accelerated growth and strategic transformation. He previously held senior leadership roles at Cardiocore (acquired by BioTelemetry), Thermo Fisher Scientific, and Pfizer, where he spent 15 years in progressively senior commercial positions. Mr. Goodman currently serves on the board of Fourth Frontier. He is a retired U.S. Army officer and holds a B.S. degree from Norwich University.- Robert S. Goodman，于2025年6月加入董事会。古德曼先生为《财富》50强企业带来了30多年的执行商业领导经验和跨越风险投资支持的新兴业务的成功。最近，他在开创性的健康科技公司Fourth Frontier的董事会任职，在那里他为该公司的510k FDA设备批准做出了贡献，并支持了成功的B轮融资。Goodman先生在2023-2024年期间担任制药公司WEP Clinical的首席商务官，帮助加速并提高了总合同价值和收入同比增长超过30%。古德曼先生曾在BioTelemetry担任部门总裁，并在2021年带领皇家飞利浦进行了一笔2.1亿美元的卖方交易。Goodman先生还拥有丰富的执行销售经验，曾于2008-2017年担任Cardiocore（后被BioTelemetry收购）的销售与营销高级副总裁，并于2007-2008年担任赛默飞世尔的高级董事、销售与营销主管。
- Robert S. Goodman was appointed as a director of the Company on June 16, 2025. Mr. Goodman has also served as Chief Commercial Officer since November 2025. He was appointed to serve as the Chief Executive Officer. He has over 25 years of experience in sales strategy, go to market execution, strategic partnerships and growth management. He has been instrumental in shaping the Company's recent commercial approach and is widely recognized for his ability to expand market penetration and accelerate product adoption in competitive healthcare sectors. Prior to joining Beyond Air, Mr. Goodman served as Chief Commercial Officer at WEP Clinical from 2023 to 2024, and ActiGraph from 2022 to 2023, where he led global commercial operations and go to market execution. Earlier in his career, he spent more than nine years at BioTelemetry, Inc. (acquired by Royal Philips), including as Division President and Business Head of BioTel Care and Alliance from and Senior Vice President of Global Sales and Marketing at BioTel Research, helping scale multiple businesses through periods of accelerated growth and strategic transformation. He previously held senior leadership roles at Cardiocore (acquired by BioTelemetry), Thermo Fisher Scientific, and Pfizer, where he spent 15 years in progressively senior commercial positions. Mr. Goodman currently serves on the board of Fourth Frontier. He is a retired U.S. Army officer and holds a B.S. degree from Norwich University.